{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/bronchiectasis/prescribing-information/erythromycin/","result":{"pageContext":{"chapter":{"id":"5217d027-064d-5543-93b0-7e8bb1a1c0fc","slug":"erythromycin","fullItemName":"Erythromycin","depth":2,"htmlHeader":"<!-- begin field c351e1bc-9175-4ac5-ad6a-a8d20eec7d7a --><h2>Erythromycin</h2><!-- end field c351e1bc-9175-4ac5-ad6a-a8d20eec7d7a -->","summary":"","htmlStringContent":"<!-- begin item 105d3fc6-02b5-4974-a0a1-34d4c24c1cec --><!-- end item 105d3fc6-02b5-4974-a0a1-34d4c24c1cec -->","topic":{"id":"96a8622b-46f5-55fa-b729-6748e3d98c98","topicId":"26fab339-e333-44ec-a481-de87a29052f3","topicName":"Bronchiectasis","slug":"bronchiectasis","lastRevised":"Last revised in January 2021","chapters":[{"id":"43d88c30-f768-5e1c-a6ea-5596c5577fb5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ac4fde9a-5fd3-5ed9-9201-f714bda470bb","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0b34af83-d49a-5145-8589-e8748b8646c0","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"04eeb1ae-4fc3-5418-83a2-b62587d8bdda","slug":"changes","fullItemName":"Changes"},{"id":"dbd8ad5a-871c-59b8-9729-444e11ac9df1","slug":"update","fullItemName":"Update"}]},{"id":"b89644c6-805f-50b4-991d-36bb2b0fbf67","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d38de329-73b8-5fed-83ef-f836b765cd3f","slug":"goals","fullItemName":"Goals"},{"id":"3c116665-5586-5551-909c-0efc1ef0be62","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"60e13bc0-e351-5c39-b8ff-9a8d4514bf16","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"2ee37cc0-9ff4-5bbd-ab3f-0a30cb904bb5","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d155aa4f-7dfe-575d-a7dd-a87774f4cbad","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"07c3e24b-c950-516e-9070-5441a07b3791","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"5146c866-f0a7-54a6-a5ac-8aff4b385cc6","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e2107a7e-b7c3-5ba9-94e4-6217ea79a3f2","slug":"definition","fullItemName":"Definition"},{"id":"39df7c47-de08-57ae-aa40-89a7d4d7b031","slug":"causes","fullItemName":"Causes"},{"id":"ac4d346e-97d4-5d84-a704-fbdcf56be7f4","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e07a8b0b-866c-5789-85ef-020a5b19b620","slug":"prognosis-complications","fullItemName":"Prognosis and complications"}]},{"id":"ef5c5e7b-3cf4-5939-85e0-b61cae41f945","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ce267b5b-70dd-52bd-ad83-6123bd42fa0d","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"c605c0b9-0519-50e1-abd8-2dc47de7278a","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"23a1627d-30f7-5ba4-95f8-060faf797f51","slug":"suspected-infective-exacerbation-diagnosis","fullItemName":"Suspected infective exacerbation diagnosis"}]},{"id":"5a5846fa-c8b4-5cd4-b2d3-770c3dc00ba2","fullItemName":"Management","slug":"management","subChapters":[{"id":"0180d43c-dd8d-5a87-915c-629542f782fe","slug":"suspected-bronchiectasis","fullItemName":"Scenario: Suspected bronchiectasis"},{"id":"290c51ae-6521-5c03-b12e-117e40c88883","slug":"infective-exacerbation","fullItemName":"Scenario: Infective exacerbation"},{"id":"1e90ec28-8eea-5ab7-ac76-2df1ace279de","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"ba1a593e-f80b-5c5f-be50-5979b491bc70","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"6db0266e-4d15-5eec-b2c0-ed20f472eeb5","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"a98b5813-5589-5247-9c65-e9ae534d88c2","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"04c99c8f-7a1d-55f0-85a2-6d0e1bc3e4e3","slug":"ciprofloxacin","fullItemName":"Ciprofloxacin"},{"id":"26b521e3-9c5e-5a7c-956b-7f3f39f2e58c","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"6cd6079a-be84-5279-9d10-e3bf4653c049","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"8ed4a900-3e69-51c0-8cd5-c2b0bee9bfe2","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"5217d027-064d-5543-93b0-7e8bb1a1c0fc","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"cf1fbf18-e60a-54f7-bbc4-2a30ab37f565","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"8e888abe-cb05-5343-b6e3-547dea7312cc","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"}]},{"id":"118b4e08-e6ae-510a-b2f5-51b109ef3395","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"ecf8de37-d8f0-5ced-af38-9be20fa73de9","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1c227675-02ea-5c9e-a927-e385987adf53","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f74bbe64-1998-528f-b811-df2a14219de7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2a925d45-6865-5cd5-9624-23da53ee221a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"a6ff3076-9be6-55b4-b373-f40cb3045f2c","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"67608f46-5eba-58f9-86e3-0e0e3f57d921","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3fae7f8d-20fb-5fe6-af57-64882afceb3a","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ba1a593e-f80b-5c5f-be50-5979b491bc70","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"97d569df-2dc6-5cf1-b717-da33ced4b5db","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field bab3437c-19c7-4975-a91e-6159727824d6 --><h3>What contraindications and cautions are associated with erythromycin?</h3><!-- end field bab3437c-19c7-4975-a91e-6159727824d6 -->","summary":"","htmlStringContent":"<!-- begin item 28e1baa0-b458-4956-9711-dcf9c35e0c4d --><!-- begin field 1a96da9f-b139-4faa-8322-8b206a56ddd1 --><ul><li><strong>Do not prescribe erythromycin to people with:</strong><ul><li>Electrolyte disturbances.</li><li>A history of QT interval prolongation, or ventricular cardiac arrhythmia. </li><li>Conditions that predispose to QT interval prolongation such as electrolyte disturbances and people taking drugs that prolong the QT interval. </li></ul></li><li><strong>Prescribe erythromycin with caution to people with:</strong><ul><li>Coronary artery disease, severe cardiac insufficiency, conductive disturbances, or clinically relevant bradycardia.</li><li>Hepatic impairment (or people concomitantly receiving potentially hepatotoxic drugs) — erythromycin is mainly excreted by the liver.</li><li>Moderate to severe renal impairment:<ul><li>Give a maximum dose for erythromycin of 1.5 g a day in severe renal impairment due to the risk of ototoxicity.</li></ul></li><li>Myasthenia gravis — macrolides may aggravate weakness symptoms.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">ABPI, 2020h</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">Joint Formulary Committee, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">MHRA, 2020</a>]</p><!-- end field 1a96da9f-b139-4faa-8322-8b206a56ddd1 --><!-- end item 28e1baa0-b458-4956-9711-dcf9c35e0c4d -->","subChapters":[]},{"id":"6f5cfda5-cd13-58ac-a275-2af9ec8faeb8","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 35c9e2bc-56af-4b78-b5f3-1cd9c39af706 --><h3>What are the adverse effects of erythromycin?</h3><!-- end field 35c9e2bc-56af-4b78-b5f3-1cd9c39af706 -->","summary":"","htmlStringContent":"<!-- begin item 98cd72c4-5af6-4fc4-bc7f-1704222bce1b --><!-- begin field 19179091-fcc1-4c70-b8e4-732c8415288f --><ul><li><strong>Gastrointestinal</strong> <strong>(GI)</strong> — diarrhoea, GI discomfort/disorders, nausea, vomiting (common or very common); constipation (uncommon).<ul><li><strong>Rare or very rare:</strong> antibiotic-associated colitis. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li><strong>Cardiovascular</strong> — QTc interval prolongation, torsades de pointes, palpitations, and cardiac rhythm disorders including ventricular tachyarrhythmias (uncommon).</li><li><strong>Hepatobiliary </strong>— cholestatic hepatitis, jaundice, hepatic disfunction, hepatomegaly, hepatic failure, hepatocellular hepatitis.</li><li><strong>Skin and subcutaneous tissues</strong> — skin reactions (common or very common); Stevens–Johnson syndrome, toxic epidermal necrolysis, erythema multiforme (uncommon); acute generalized exanthematous pustulosis (AGEP) (frequency unknown).</li><li><strong>Other common adverse effects include:</strong><ul><li>Dizziness.</li><li>Headache.</li><li>Hearing impairment — this can occur after large doses of erythromycin (more than 4 g).</li><li>Vasodilation.</li><li>Vision disorders.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">ABPI, 2020h</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 19179091-fcc1-4c70-b8e4-732c8415288f --><!-- end item 98cd72c4-5af6-4fc4-bc7f-1704222bce1b -->","subChapters":[]},{"id":"a979b12c-90ad-5399-b1fd-1c92f38882ed","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 54948315-1f57-4966-87f4-66de0d01184e --><h3>What drug interactions are important with erythromycin?</h3><!-- end field 54948315-1f57-4966-87f4-66de0d01184e -->","summary":"","htmlStringContent":"<!-- begin item 85487b6c-7e53-48b5-babb-c04239bfc357 --><!-- begin field 25da968d-5360-4e80-98f9-ec786dc374e3 --><ul><li><strong>Aminophylline</strong> — aminophylline can cause hypokalaemia (potentially increasing the risk of torsades de pointes) when given with erythromycin. Theophylline clearance may also be reduced if given concurrently with erythromycin. Monitor theophylline levels after 48 hours and adjust the dose accordingly. Monitor potassium concentrations closely and the effects of oral erythromycin to ensure they are adequate. Consider giving an alternative antibiotic. </li><li><strong>Calcium channel blockers </strong>(amlodipine, diltiazem) — erythromycin possibly inhibits the metabolism of calcium channel blockers, increasing the risk of adverse effects, such as hypotension. Monitor for adverse effects (for example, bradycardia, hypotension, headache, oedema) and reduce the calcium-channel blocker dose as necessary.</li><li><strong>Rifampicin</strong> — may induce the metabolism of clarithromycin, resulting in sub-therapeutic levels. If concurrent use is necessary, monitor erythromycin efficacy closely.</li><li><strong>Carbamazepine </strong>— erythromycin can increase carbamazepine levels, causing carbamazepine toxicity (which may present as nausea and vomiting, ataxia, and drowsiness).<ul><li>Avoid concurrent use, unless carbamazepine levels can be monitored closely.</li></ul></li><li><strong>Ciclosporin</strong> — levels are greatly increased by erythromycin. Monitor concentrations and effects (for example, renal function) more frequently if erythromycin is started or stopped. Adjust the ciclosporin dose as required. </li><li><strong>Cisapride, domperidone</strong> — levels may be raised, increasing the risk of potentially life-threatening arrhythmias (torsades de pointes). Concurrent use is contraindicated.</li><li><strong>Colchicine </strong>— erythromycin possibly increases the risk of colchicine toxicity.<ul><li>Stop or reduce the dose of colchicine.</li><li>Avoid concomitant use in renal or hepatic impairment.</li></ul></li><li><strong>Drugs that prolong the QT interval</strong> (such as amiodarone, amisulpride, fluconazole, sildenafil, mizolastine, hydroxyzine) — macrolides can also prolong the QT interval, increasing the risk of arrhythmias (such as torsades de pointes).<ul><li>Concurrent use of drugs that prolong the QT interval is not recommended.</li></ul></li><li><strong>Drugs that cause hypokalaemia</strong> (such as diuretics, corticosteroids, short-acting beta-2 agonists) — hypokalaemia is a risk factor for QT prolongation. Monitor potassium levels closely. </li><li><strong>Digoxin</strong> — erythromycin may increase the concentration of digoxin. <ul><li>Monitor digoxin concentration.</li></ul></li><li><strong>Ergot alkaloids </strong>(such as ergotamine and dihydroergotamine)<strong> </strong>— concurrent use with erythromycin may result in acute ergot toxicity. Concurrent use is contraindicated.</li><li><strong>Protease inhibitors</strong> (ritonavir, saquinavir) — erythromycin levels may be increased. Monitor for adverse effects. </li><li><strong>Statins </strong>— there is an increased risk of myopathy (due to cytochrome P450 enzyme CYP3A4 inhibition) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">MHRA, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">MHRA, 2014</a>].    <ul><li>For simvastatin (potent CYP3A4 inhibitor) — concurrent use is contraindicated. If erythromycin treatment cannot be avoided, stop treatment with simvastatin during the course of the treatment.</li><li>For atorvastatin (moderate CYP3A4 inhibitor) — avoid concurrent use if possible. If erythromycin treatment cannot be avoided, stop treatment with simvastatin during the course of the treatment or prescribe the lowest starting dose of atorvastatin (that is 10 mg) and do not exceed 20 mg atorvastatin daily. Advise the person to seek medical advice if they experience symptoms of myopathy (for example muscle pain, tenderness, or weakness).</li><li>For pravastatin — prescribe erythromycin with caution, and advise the person to report any muscle pain, tenderness, or weakness.</li></ul></li><li><strong>Theophylline </strong>— erythromycin possibly increases the plasma concentration of theophylline. Monitor theophylline levels after 48 hours and adjust the theophylline dose if necessary.</li><li><strong>Typhoid vaccine </strong>— antibacterials might reduce the immune response. The World Health Organization (WHO) recommends that the antibacterial is stopped from 3 days before to 3 days after receiving live oral typhoid vaccine.</li><li><strong>Quetiapine </strong>— erythromycin increases the plasma concentration of quetiapine and both drugs are associated with QT interval prolongation. Concurrent use is contraindicated, but if necessary, monitor for quetiapine adverse effects (for example, somnolence, dry mouth, tachycardia) and reduce the dose if needed.</li><li><strong>Rivaroxaban — </strong>erythromycin may increase levels of rivaroxaban, increasing the risk of bleeding. </li><li><strong>Warfarin </strong>— erythromycin may cause a minor increase in warfarin effects. Consider increased monitoring of the international normalized ratio (INR) when both drugs are used (particularly in elderly people), and adjust the warfarin dose accordingly. </li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are <em>not</em> required during or after a course of erythromycin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">FSRH, 2019</a>]. <ul><li>However, advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the section on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">Preston, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">MHRA, 2020</a>]</p><!-- end field 25da968d-5360-4e80-98f9-ec786dc374e3 --><!-- end item 85487b6c-7e53-48b5-babb-c04239bfc357 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}